Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?
| ISRCTN | ISRCTN57354520 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN57354520 |
| Secondary identifying numbers | RAJ001 |
- Submission date
- 21/02/2006
- Registration date
- 29/03/2006
- Last edited
- 10/07/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Narasimharajapura Rajendra
Scientific
Scientific
Department of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
DD1 9SY
United Kingdom
Study information
| Study design | Randomised double-blind placebo-controlled parallel group |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised parallel trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction? |
| Study objectives | Allopurinol, by inhibiting xanthine oxidase brings about a reduction in reactive oxygen species, thereby preventing adverse remodelling |
| Ethics approval(s) | Regional Ethics Committee, 07/12/2005, ref: 05/S1401/171 |
| Health condition(s) or problem(s) studied | Myocardial infarction |
| Intervention | Allopurinol versus placebo |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Allopurinol |
| Primary outcome measure | Assessment of remodelling |
| Secondary outcome measures | Brain natriuretic peptide (BNP) |
| Overall study start date | 10/02/2006 |
| Completion date | 02/04/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 36 |
| Key inclusion criteria | Post myocardial infarction - days 3 to 14 |
| Key exclusion criteria | 1. Renal failure 2. Concomitant warfarin therapy 3. Allopurinol allergy |
| Date of first enrolment | 10/02/2006 |
| Date of final enrolment | 02/04/2008 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
Ninewells Hospital
Dundee
DD1 9SY
United Kingdom
DD1 9SY
United Kingdom
Sponsor information
University of Dundee (UK)
University/education
University/education
The Nethergate
University of Dundee
Dundee
DD1 4HN
Scotland
United Kingdom
"ROR" |
https://ror.org/03h2bxq36 |
|---|
Funders
Funder type
Charity
British Heart Foundation
Private sector organisation / Trusts, charities, foundations (both public and private)
Private sector organisation / Trusts, charities, foundations (both public and private)
- Alternative name(s)
- the_bhf, The British Heart Foundation, BHF
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
10/07/2017: No publications found, verifying study status with principal investigator.
